Loading
Everything OnCo dates to 2014: 355 entries, 91 papers listed on people's pages, 89 papers, 72 landmarks and 38 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
355 dated entries in OnCo fall in 2014: 91 papers listed on people's pages, 89 papers, 72 landmarks, 38 approvals, 37 trials reported, 11 companies founded, 9 regulatory events, 5 technologies, 2 journals founded and 1 law or regulation.
Of those, 8 to the day, 1 to the month and 346 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Relapsed/refractory peripheral T-cell lymphoma
Platinum-resistant ovarian cancer with chemotherapy; recurrent/metastatic cervical cancer with chemotherapy
Relapsed/refractory B-ALL
Companion diagnostic for olaparib in germline BRCA-mutated advanced ovarian cancer
Cometriq for medullary thyroid cancer; 21 Mar 2014. Cabometyx (RCC) Sep 2016
ALK-positive metastatic NSCLC after crizotinib
Colorectal cancer screening in average-risk adults aged 50 and older (later 45 and older)
BRAF V600E/K unresectable or metastatic melanoma, combination (accelerated; each drug alone approved 2013)
With trametinib: BRAF V600E/K metastatic melanoma; later adjuvant melanoma, BRAF V600E NSCLC, anaplastic thyroid cancer, tumour-agnostic solid tumours and paediatric low-grade glio...
Relapsed mantle cell lymphoma; CLL after one prior therapy or with del(17p)/TP53 mutation
Relapsed CLL (RESONATE); del(17p) CLL
First-line EGFR-mutant NSCLC
CLL, FL
Relapsed CLL with rituximab; relapsed FL and SLL (accelerated, withdrawn 2022)
Oral suspension for ALL maintenance (Purixan)
Acute and delayed chemotherapy-induced nausea and vomiting including highly emetogenic regimens, with dexamethasone (intravenous form 2018)
Adenocarcinoma NSCLC after first-line chemotherapy, with docetaxel
Idiopathic pulmonary fibrosis (non-oncology)
Melanoma
Prevention of HPV-related cancers and precancers, ages 9-26; extended to 45 in 2018
Previously untreated CLL with chlorambucil; later extended treatment and relapsed CLL with fludarabine and cyclophosphamide
gBRCA ovarian cancer ≥3 lines
First-line RAS wild-type mCRC with FOLFOX
Acromegaly inadequately controlled by surgery or for whom surgery is not an option (long-acting depot)
Melanoma (first of >40 indications)
Proliferating infantile haemangioma requiring systemic therapy
Gastric cancer; NSCLC
Advanced gastric or gastro-oesophageal junction adenocarcinoma after two or more lines
Polycythaemia vera after hydroxyurea
Multicentric Castleman disease in HIV-negative and HHV-8-negative adults
Multicentric Castleman disease in HIV-negative and HHV-8-negative patients
Unresectable GEP-NETs to improve PFS (lanreotide)
Sentinel node imaging in breast cancer, melanoma, oral SCC
Sentinel lymph node localisation in oral cavity squamous cell carcinoma
BRAF V600 melanoma alone or with dabrafenib; later NSCLC and adjuvant melanoma
With dabrafenib: metastatic melanoma; later adjuvant melanoma, NSCLC, anaplastic thyroid cancer, tumour-agnostic BRAF V600E solid tumours, paediatric low-grade glioma
Relapsed or refractory peripheral T-cell lymphoma
Not recommended. TA307, published 25 March 2014: aflibercept with irinotecan and fluorouracil-based therapy is not recommended within its marketing authorisation; patients already...
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
Relapsed CLL
First-line with FOLFOX in RAS wild-type (PRIME)
First PD-1 inhibitor approved worldwide (melanoma, Japan)
Cervical cancer with chemotherapy (GOG-0240)
Accelerated approval, advanced melanoma after ipilimumab; first PD-1 inhibitor in the US
Accelerated approval, Ph-negative relapsed/refractory B-ALL: first BiTE
Gardasil 9 approved
gBRCA advanced ovarian cancer after ≥3 lines: first PARP inhibitor
Advanced melanoma after ipilimumab (accelerated)
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
European Union, regulation.
The year reported on trial records, with the headline result the record gives.
Median progression-free survival 6.7 months with bevacizumab plus chemotherapy against 3.4 months with chemotherapy alone (hazard ratio 0.48, p < 0.001); response rate 27.3 against...
Bevacizumab added to radiotherapy and temozolomide prolonged progression-free survival but not overall survival in newly diagnosed glioblastoma.
Median overall survival 11.2 against 10.0 months (hazard ratio 0.85, 95 percent confidence interval 0.72 to 1.00, p=0.053), missing significance; hazard ratio 1.46 in the first 5 m...
PFS HR 0.47.
Median progression-free survival 12.3 vs 7.2 months (HR 0.58); median overall survival 22.3 vs 17.4 months (HR 0.70).
3-year EFS 53.1% vs 46.9%, HR 0.83; relapse risk reduced.
Median progression-free survival 11.0 vs 8.8 months; median overall survival 25.1 vs 18.7 months (HR 0.71); pooled COMBI-d/v 5-year overall survival 34%.
Median overall survival 5.9 months with OFF against 3.3 months with FF (hazard ratio 0.66, 95 percent confidence interval 0.48 to 0.91; p 0.010); time to progression 2.9 against 2...
Sensitivity 92.3% for colorectal cancer (FIT 73.8%); specificity 86.6% (FIT 94.9%).
Median OS 14.3 vs 12.8 months (HR 0.83, not significant); median PFS 7.4 vs 4.6 months (HR 0.74).
4 Gy was not non-inferior to 24 Gy for local control: five-year local progression-free rate 89.9 percent after 24 Gy against 70.4 percent after 4 Gy (hazard ratio 3.46).
Carboplatin increased pathological complete response and improved disease-free survival in triple-negative breast cancer, without benefit in HER2-positive disease.
Three-year progression-free survival 59 percent with marker-guided dose-dense chemotherapy against 48 percent with BEP (hazard ratio 0.66, p 0.05); salvage high-dose chemotherapy n...
Median progression-free survival 3.4 against 2.7 months (hazard ratio 0.79, p=0.0019); overall survival significant in the adenocarcinoma populations of the prespecified hierarchy...
Ten-year cumulative recurrence 4.4 per cent after Mohs surgery against 12.2 per cent after ordinary excision for primary high-risk facial basal cell carcinoma (p=0.100), and 3.9 ag...
Cervical cancer mortality rate ratio 0.69 (31% reduction).
No disease-free survival benefit from cetuximab in KRAS wild-type disease (hazard ratio 1.05).
Radiographic progression-free survival at 12 months 65 against 14 percent (hazard ratio 0.19, 95 percent confidence interval 0.15 to 0.23) and hazard ratio for death 0.71 (0.60 to...
Objective response 72 percent (36 of 50); median duration of response 17.6 months; median progression-free survival 19.2 months.
Median progression-free survival 10.9 against 7.0 months (hazard ratio 0.45, 95 percent confidence interval 0.35 to 0.60).
OS 9.6 vs 7.4 months, HR 0.81.
PFS HR 0.22; median PFS 44.1 vs 8.1 months (6-year).
Median overall survival 10.5 against 9.1 months (hazard ratio 0.86, p=0.023); progression-free survival 4.5 against 3.0 months.
Exemestane + OFS: DFS and DRFI improved; no OS difference at 12 years.
Progression-free survival 12.1 against 9.7 months (hazard ratio 0.75); response rate 65 against 53 percent.
The publication year on key paper records.
Gamis AS, Alonzo TA, Meshinchi S, et al. Journal of Clinical Oncology.
Kuhl CK, Schrading S, Strobel K, et al. Journal of Clinical Oncology.
Ito Y, Miyauchi A, Kihara M, et al. Thyroid.
Golfier S, Kopitz C, Kahnert A, et al. Molecular Cancer Therapeutics.
Jain RK. Cancer Cell.
Antonarakis ES, Lu C, Wang H, et al. New England Journal of Medicine.
Murray IA, Patterson AD, Perdew GH. Nature Reviews Cancer.
Pujade-Lauraine E, Hilpert F, Weber B, et al. Journal of Clinical Oncology.
Chinot OL, Wick W, Mason W, et al. New England Journal of Medicine.
Fernandez-Cuesta L, Plenker D, Osada H, et al. Cancer Discovery.
Chmielecki J, Hutchinson KE, Frampton GM, et al. Cancer Discovery.
Aceto N, Bardia A, Miyamoto DT, et al. Cell.
Caplin ME, Pavel M, Ćwikła JB, et al. New England Journal of Medicine.
Noh SH, Park SR, Yang HK, et al. The Lancet Oncology.
Long GV, Stroyakovskiy D, Gogas H, et al. New England Journal of Medicine.
Larkin J, Ascierto PA, Dréno B, et al. New England Journal of Medicine.
Pritchard CC, Morrissey C, Kumar A, et al. Nature Communications.
Cancer Genome Atlas Research Network. Nature.
Cancer Genome Atlas Research Network. Nature.
Shaw AT, Ou SH, Bang YJ, et al. New England Journal of Medicine.
Brose MS, Nutting CM, Jarzab B, et al. The Lancet.
Pramesh CS, Badwe RA, Borthakur BB, et al. The Lancet Oncology.
Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Cancer Cell.
Stoeck A, Lejnine S, Truong A, et al. Cancer Discovery.
Missiaglia E, Jacobs B, D'Ario G, et al. Annals of Oncology.
Primrose JN, Perera R, Gray A, et al. JAMA.
Shastri SS, Mittra I, Mishra GA, et al. JNCI: Journal of the National Cancer Institute.
Judson I, Verweij J, Gelderblom H, et al. The Lancet Oncology.
Mack SC, Witt H, Piro RM, et al. Nature.
Barton MB, Jacob S, Shafiq J, et al. Radiotherapy and Oncology.
Copson E, Maishman T, Gerty S, et al. British Journal of Cancer.
Piccart M, Hortobagyi GN, Campone M, et al. Annals of Oncology.
Brastianos PK, Taylor-Weiner A, Manley PE, et al. Nature Genetics.
Solomon BJ, Mok T, Kim DW, et al. New England Journal of Medicine.
Heinemann V, von Weikersthal LF, Decker T, et al. The Lancet Oncology.
Hoskin PJ, Kirkwood AA, Popova B, et al. The Lancet Oncology.
Sharma P, Klemp JR, Kimler BF, et al. Breast Cancer Research and Treatment.
Fizazi K, Pagliaro L, Laplanche A, et al. The Lancet Oncology.
Tewari KS, Sill MW, Long HJ, et al. New England Journal of Medicine.
Viale G, Slaets L, Bogaerts J, et al. Annals of Oncology.
Weinreb I, Piscuoglio S, Martelotto LG, et al. Nature Genetics.
Mesri EA, Feitelson MA, Munger K. Cell host & microbe.
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. The Lancet Oncology.
Sharpe M, Walker J, Holm Hansen C, et al. The Lancet.
Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Blood.
Jaiswal S, Fontanillas P, Flannick J, et al. New England Journal of Medicine.
Ahn HS, Kim HJ, Welch HG. New England Journal of Medicine.
Lamouille S, Xu J, Derynck R. Nature Reviews Molecular Cell Biology.
Ruffell B, Chang-Strachan D, Chan V, et al. Cancer Cell.
Maude SL, Frey N, Shaw PA, et al. New England Journal of Medicine.
Sosa MS, Bragado P, Aguirre-Ghiso JA. Nature Reviews Cancer.
Gandini S, Puntoni M, Heckman-Stoddard BM, et al. Cancer prevention research.
Venderbosch S, Nagtegaal ID, Maughan TS, et al. Clinical Cancer Research.
Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. New England Journal of Medicine.
von Minckwitz G, Schneeweiss A, Loibl S, et al. The Lancet Oncology.
Golan T, Kanji ZS, Epelbaum R, et al. British Journal of Cancer.
Loeb S, Bjurlin MA, Nicholson J, et al. European Urology.
Roa I, de Toro G, Schalper K, et al. Gastrointestinal Cancer Research.
Paganetti H. International Journal of Radiation Oncology, Biology, Physics.
Cortazar P, Zhang L, Untch M, et al. The Lancet.
Topp MS, Gökbuget N, Zugmaier G, et al. Journal of Clinical Oncology.
Lenders JW, Duh QY, Eisenhofer G, et al. The Journal of Clinical Endocrinology & Metabolism.
Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-Lahad E.
Lee W, Teckie S, Wiesner T, et al. Nature Genetics.
Beer TM, Armstrong AJ, Rathkopf DE, et al. New England Journal of Medicine.
Yang W, Williams JH, Hogan PF, et al. JCO Oncology Practice.
Epstein JI, Amin MB, Beltran H, et al. American Journal of Surgical Pathology.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Cancer Research.
Wilke H, Muro K, Van Cutsem E, et al. The Lancet Oncology.
Cheson BD, Fisher RI, Barrington SF, et al. Journal of Clinical Oncology.
Paganetti H. Physics in medicine and biology.
Russell SJ, Federspiel MJ, Peng KW, et al. Mayo Clinic Proceedings.
Siegel R, Ma J, Zou Z, Jemal A. CA: A Cancer Journal for Clinicians.
Treon SP, Cao Y, Xu L, et al. Blood.
Rhim AD, Oberstein PE, Thomas DH, et al. Cancer Cell.
Nagaraja V, Eslick GD. Alimentary Pharmacology and Therapeutics.
Roberts KG, Li Y, Payne-Turner D, et al. New England Journal of Medicine.
Lineweaver CH, Davies PC, Vincent MD. BioEssays.
Pramesh CS, Badwe RA, Sinha RK. Indian journal of medical and paediatric oncology.
Therkildsen C, Bergmann TK, Henrichsen-Schnack T, et al. Acta oncologica.
Pantziarka P, Bouche G, Meheus L, et al. Ecancermedicalscience.
Davis CF, Ricketts CJ, Wang M, et al. Cancer Cell.
Kelley LC, Lohmer LL, Hagedorn EJ, et al. The Journal of cell biology.
Tumeh PC, Harview CL, Yearley JH, et al. Nature.
Korolev KS, Xavier JB, Gore J. Nature Reviews Cancer.
Rueth NM, Lin HY, Bedrosian I, et al. Journal of Clinical Oncology.
Howlader N, Altekruse SF, Li CI, et al. Journal of the National Cancer Institute.
Kris MG, Johnson BE, Berry LD, et al. JAMA.
Li M, Zhang Z, Li X, et al. Nature Genetics.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Acute myeloid leukaemia in children
Platinum-resistant ovarian cancer
Glioma & glioblastoma
Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)
Cervical cancer
Relapsed and refractory acute lymphoblastic leukaemia in children
Acute lymphoblastic leukaemia. Accelerated approval in relapsed/refractory Ph-negative B-ALL.
Acute lymphoblastic leukaemia
Craniopharyngioma. Brastianos and colleagues (Nature Genetics) show near-universal BRAF V600E in PCP and CTNNB1 in ACP.
Ependymoma. Parker and colleagues (Nature) link the fusion to NF-kB activation.
Triple-negative breast cancer (TNBC). GeparSixto and CALGB 40603 show platinum increases pathologic complete response.
Langerhans cell histiocytosis (LCH). Berres and colleagues (JEM) show BRAF V600E in myeloid precursors in high-risk disease.
Neuroendocrine tumours
Pancreatic neuroendocrine tumours
Small intestinal neuroendocrine tumours
BRAF V600-mutant melanoma
Waldenström macroglobulinaemia. Present in ~30% and associated with BTKi resistance.
Hepatocellular carcinoma. HCC risk falls ~70% after cure.
Pheochromocytoma and paraganglioma (PPGL)
Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)
Undifferentiated pleomorphic sarcoma (UPS)
Soft tissue sarcoma of the extremity (localised and advanced)
Uterine sarcoma. Unsuspected uterine sarcoma disseminated by morcellation during fibroid surgery.
Gallbladder cancer. 57 Chinese tumours: TP53 47%, ERBB3 12%, ErbB pathway in 37% with worse survival (Li et al., Nature Genetics).
Newly diagnosed multiple myeloma, transplant-ineligible
Early triple-negative breast cancer
Non-seminomatous germ cell tumour
Recurrent or metastatic cervical cancer
Thymoma (WHO types A, AB, B1, B2 and B3)
Thymoma and thymic carcinoma
Chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia, first treatment
Chronic lymphocytic leukaemia. PFS HR 0.22 vs ofatumumab; the BTK era begins. Idelalisib approved the same year.
Smouldering multiple myeloma
Hodgkin lymphoma
Diffuse large B-cell lymphoma
Leiomyosarcoma
Myxofibrosarcoma
Platinum-sensitive ovarian cancer
Ovarian cancer
Ovarian cancer. For germline BRCA-mutated ovarian cancer after three lines.
High-grade serous ovarian cancer
Skin cancer (all types). Pembrolizumab and nivolumab approved for advanced melanoma, later moving to adjuvant and neoadjuvant use.
Melanoma
Melanoma
Advanced melanoma (unresectable stage III and stage IV)
Malignant peripheral nerve sheath tumour (MPNST)
ROS1-positive non-small-cell lung cancer
ALK-positive non-small-cell lung cancer
Relapsed or refractory chronic lymphocytic leukaemia
BRCA or PALB2-mutant pancreatic ductal adenocarcinoma
Localised small bowel adenocarcinoma (stage I to III, resected)
Polycythaemia vera (PV). FDA approval in December 2014 for hydroxyurea-resistant or intolerant PV on the RESPONSE trial; EU approval followed in 2015.
Pancreatic acinar cell carcinoma
Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)
Skin cancer (all types). 501 people randomised in the United Kingdom; clinical success at three years 84 against 98 per cent and at five years 82.5 against 97.7 per cent.
Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma
High-risk early HR-positive breast cancer
HR-positive / HER2-negative breast cancer
Papillary thyroid cancer
Testicular germ cell tumours
Solid pseudopapillary neoplasm of the pancreas
Microsatellite-unstable (MSI-high) gastric cancer
Chromophobe renal cell carcinoma
Gastric & gastro-oesophageal junction cancer
Non-small-cell lung cancer. Two hundred and thirty adenocarcinomas profiled on every platform add RIT1 and MGA to the driver list and show that NF1, MET, ERBB2 and RIT1 drive the t...
Prostate cancer. Antonarakis found AR-V7, an androgen receptor lacking the part the drugs bind, in circulating tumour cells: a zero percent prostate-specific antigen response rate...
Prostate cancer. The Prostate Cancer Foundation working committee publishes the six categories that separate incidental neuroendocrine staining from small cell carcinoma, which is...
Metastatic triple-negative breast cancer
Triple-negative breast cancer (TNBC). Copson and colleagues, 2,915 women aged 40 or under: 26.1 vs 18.6 percent triple-negative; five-year survival 71.1 vs 82.4 percent with equal...
Uterine carcinosarcoma
Localised prostate cancer, intermediate risk
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
San Francisco, CA
Cambridge
Burlingame, California
Paris
Lyon
Philadelphia, PA
Nijmegen
Shanghai
Beijing
Boston, Massachusetts
Shanghai / Cambridge, MA
The founded year on journal records.
S. Karger AG
Elsevier
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Journal of Thoracic Oncology
Cell
Nature Medicine
Oncoimmunology
Cell
PNAS
Annals of Internal Medicine
Nature
New England Journal of Medicine
New England Journal of Medicine
Journal of Cancer
NEJM
Oncotarget
Cell
Respiratory Investigation
Journal of Clinical Oncology
Thyroid®
The Lancet Oncology
The Lancet Oncology
Lancet Respir Med
J Am Coll Cardiol
Nat Rev Immunol
Clinical Cancer Research
JAMA
Molecular Oncology
American Journal of Disaster Medicine
Nature Reviews Clinical Oncology
NEJM
memo - Magazine of European Medical Oncology
memo - Magazine of European Medical Oncology
Journal of Clinical Investigation
New England Journal of Medicine
Annual Review of Pathology
NEJM
Blood
Nature
Leukemia
Cancer Immunology Research
NEJM
Asian Pac J Cancer Prev
Oncotarget
Lancet Oncology
NEJM
The Lancet Oncology
NEJM
Science
Annals of Oncology
Nature
Cancer Letters
Nat Chem Biol
Lancet
JAMA Internal Medicine
Current Opinion in Pediatrics
Oral Oncology
Indian Journal of Medical and Paediatric Oncology
Lancet Oncology
Radiol Oncol
Nature Genetics
Journal of the National Cancer Institute
Surgical Oncology
Annals of Oncology
Cancer Epidemiology
Cancer Immunology Research
Journal of Oncology Practice
European Journal of Cancer
Haematologica
Cancer Chemotherapy and Pharmacology
Blood
Head & Neck
Radiother Oncol
Mayo Clinic Proceedings
NEJM
European Urology
Lancet Oncology
Annals of Oncology
Science
Blood
JCO
Lancet
Immunity
Immunity
Nature
Journal of Clinical Oncology
Cellular and Molecular Life Sciences
PLoS Biology
Annals of Oncology
Cancer Discovery
Journal of Clinical Oncology
Nature Medicine
Science Translational Medicine
Radiation Oncology